Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 24, 2017
What is the competitive landscape for GENZYME, and when can generic versions of GENZYME drugs launch?
GENZYME has fifteen approved drugs.| Patents: | 12 |
| Tradenames: | 12 |
| Ingredients: | 12 |
| NDAs: | 15 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
plerixafor | Injection | 24 mg/1.2 mL vials (20 mg/mL) | MOZOBIL | 12/17/2012 |
clofarabine | Injection | 1 mg/mL, 20 mL vial | CLOLAR | 2/23/2012 |
doxercalciferol | Injection | 2 mcg/mL, 1 mL in 2 mL vial | HECTOROL | 12/28/2011 |
doxercalciferol | Capsules | 1 mcg | HECTOROL | 2/12/2010 |
sevelamer carbonate | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | RENVELA | 12/30/2009 |
doxercalciferol | Capsules | 0.5 mcg and 2.5 mcg | HECTOROL | 3/25/2009 |
sevelamer carbonate | Tablets | 800 mg | RENVELA | 12/4/2008 |
sevelamer hydrochloride | Tablets | 400 mg and 800 mg | RENAGEL | 5/22/2008 |
doxercalciferol | Injection | 2 mcg/mL, 2 mL ampules | HECTOROL | 10/15/2007 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,255,336 | Amino ceramide-like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 7,265,228 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | ► Subscribe | |||||||||||||
| 6,569,889 | Amino ceramide-like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 6,897,210 | Quinazoline derivatives and pharmaceutical compositions containing them | ► Subscribe | |||||||||||||
| 7,935,692 | Methods to mobilize progenitor/stem cells | ► Subscribe | |||||||||||||
| 8,808,738 | Aliphatic amine polymer salts for tableting | ► Subscribe | |||||||||||||
| 5,034,518 | 2-fluoro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl) adenine nucleosides | ► Subscribe | |||||||||||||
| 5,916,911 | Amino ceramide--like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 7,763,738 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | ► Subscribe | |||||||||||||
| 8,779,163 | Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil | 0012318 | ► Subscribe | |||||||||||||
| European Patent Office | 1223166 | ► Subscribe | |||||||||||||
| Poland | 173643 | ► Subscribe | |||||||||||||
| Australia | 2006292672 | ► Subscribe | |||||||||||||
| South Africa | 200609110 | ► Subscribe | |||||||||||||
| European Patent Office | 1807057 | ► Subscribe | |||||||||||||
| Czech Republic | 20021344 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2005112934 | ► Subscribe | |||||||||||||
| Denmark | 1411918 | ► Subscribe | |||||||||||||
| Czech Republic | 9901039 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90029-3 | Sweden | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121 | ||||||||||||
| C/GB02/011 | United Kingdom | ► Subscribe | PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202 | ||||||||||||
| C0038 | France | ► Subscribe | PRODUCT NAME: CLOFARABINE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/334/001 DU 20060529; REGISTRATION NO/DATE AT EEC: EU/1/06/334/001 DU 20060529 | ||||||||||||
| 4 4-2015 | Slovakia | ► Subscribe | PRODUCT NAME: ELIGLUSTAT (VO FORME TARTRATU); REGISTRATION NO/DATE: EU/1/14/974 20150121 | ||||||||||||
| C/GB12/031 | United Kingdom | ► Subscribe | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804 | ||||||||||||
| 717 | Luxembourg | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121 | ||||||||||||
| 0716606/01 | Switzerland | ► Subscribe | PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004 | ||||||||||||
| C/GB10/004 | United Kingdom | ► Subscribe | PRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED | ||||||||||||
| 0150027 00161 | Estonia | ► Subscribe | PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015 | ||||||||||||
| 2009 00052 | Denmark | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,760 others who get our Drug Patent Expiration Alerts:
